Table 1.
Main patients’ characteristics at baseline
| Infliximab | Etanercept | Adalimumab | ||||
| Originator | Biosimilars | Originator | Biosimilars | Originator | Biosimilars | |
| Effective | 5292 | 17 378 | 13 354 | 11 088 | 18 378 | 21 286 |
| Mean age (SD) | 43.2 (15.9) | 43.3 (16.2) | 50.5 (15.0) | 51.8 (15.0) | 43.4 (15.3) | 45.1 (14.9) |
| Median age (Q1-Q3) | 42 (30–54) | 42 (30–55) | 50 (39–61) | 52 (40–63) | 42 (31–54) | 45 (33–56) |
| Male | 2486 (47.0) | 8415 (48.4) | 4805 (36.0) | 4143 (37.4) | 8232 (44.8) | 9492 (44.6) |
| Pathologies | ||||||
| Rheumatoid arthritis | 472 (8.9) | 1570 (9.0) | 5640 (42.2) | 5625 (50.7) | 1607 (8.7) | 3504 (16.5) |
| Ankylosing spondylitis | 806 (15.2) | 3253 (18.7) | 5447 (40.8) | 4255 (38.4) | 3570 (19.4) | 7521 (35.3) |
| Psoriatic arthritis | 155 (2.9) | 456 (2.6) | 905 (6.8) | 651 (5.9) | 620 (3.4) | 1237 (5.8) |
| Crohn’s disease | 2369 (44.8) | 7162 (41.2) | 0 (0) | 0 (0) | 6270 (34.1) | 4777 (22.4) |
| Ulcerative colitis | 1044 (19.7) | 4010 (23.1) | 0 (0) | 0 (0) | 3685 (20.1) | 2306 (10.8) |
| Psoriasis | 446 (8.4) | 927 (5.3) | 1362 (10.2) | 557 (5.0) | 1929 (10.5) | 1722 (8.1) |
| Hidradenitis suppurativa | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 188 (1) | 43 (0.2) |
| Uveitis | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 509 (2.8) | 176 (0.8) |
| Number of consultations linked to the pathology* | ||||||
| 0 | 880 (16.6) | 2613 (15.0) | 1291 (9.7) | 679 (6.1) | 1467 (8.0) | 1621 (7.6) |
| 1–2 | 1321 (25.0) | 4339 (25.0) | 2419 (18.1) | 1934 (17.4) | 3704 (20.2) | 4530 (21.3) |
| 3–4 | 1069 (20.2) | 3848 (22.1) | 3226 (24.2) | 2821 (25.4) | 4771 (26.0) | 6014 (28.3) |
| 5+ | 2022 (38.2) | 6578 (37.9) | 6418 (48.1) | 5654 (51) | 8436 (45.9) | 9121 (42.8) |
| Number of hospitalisations linked to the pathology* | ||||||
| 0 | 284 (5.4) | 667 (3.8) | 7713 (57.8) | 5838 (52.7) | 7878 (42.9) | 10 020 (47.1) |
| 1 | 1379 (26.1) | 5246 (30.2) | 3400 (25.5) | 3422 (30.9) | 5995 (32.6) | 6800 (31.9) |
| 2 | 1235 (23.3) | 4945 (28.5) | 1085 (8.1) | 961 (8.7) | 2426 (13.2) | 2535 (11.9) |
| 3+ | 2394 (45.2) | 6520 (37.5) | 1156 (8.7) | 867 (7.8) | 2079 (11.3) | 1931 (9.1) |
| Drug history* | ||||||
| Other biologics | 726 (13.7) | 3344 (19.2) | 2491 (18.7) | 2055 (18.5) | 2149 (11.7) | 2738 (12.9) |
| Other systemic | 2953 (55.8) | 10 267 (59.1) | 6859 (51.4) | 6650 (60) | 10 209 (55.6) | 11 497 (54.0) |
| Steroids | 3598 (68.0) | 12 301 (70.8) | 9387 (70.3) | 8004 (72.2) | 13 473 (73.3) | 15 007 (70.5) |
| Non-steroidal anti-inflammatory drug | 1932 (36.5) | 6881 (39.6) | 9472 (70.9) | 7698 (69.4) | 7710 (42.0) | 12 249 (57.5) |
Detailed patients’ characteristics at inclusion are presented in online supplemental tables 3–5.
*Drug history was assessed within the year before inclusion; the number of consultations linked to the pathology within 2 years before inclusion and the number of hospitalisations within 5 years before inclusion.
Q1-Q3, quarter 1-quarter 3; SD, Standard deviation.